Splenectomy and thrombosis

The case of thalassemia intermedia

A. T. Taher, K. M. Musallam, M. Karimi, A. El-Beshlawy, K. Belhoul, S. Daar, M. Saned, C. Cesaretti, M. D. Cappellini

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Background: Hypercoagulability in splenectomized patients with thalassemia intermedia (TI) has been extensively evaluated. However, clinical and laboratory characteristics of patients who eventually develop overt thromboembolic events (TEE) are poorly studied. Patients/Methods: Three Groups of TI patients (n = 73 each) were retrospectively identified from a registry involving six centers across the Middle East and Italy: Group I, all splenectomized patients with a documented TEE; Group II, age- and sex-matched splenectomized patients without TEE; and Group III, age- and sex-matched nonsplenectomized patients without TEE. Retrieved data included demographics, laboratory parameters, clinical complications, and received treatments that may influence TEE development, and reflected the period prior to TEE occurrence in Group I. Results: The mean age of Group I patients at development of TEE was 33.1 ± 11.7 years, with a male to female ratio of 33:40. TEE were predominantly venous (95%) while four patients (5%) had documented stroke. Among studied parameters, Group I patients weremore likely to have a nucleated red blood cell (NRBC) count ≥ 300 × 106 L-1, a platelet count ≥ 500 × 109 L-1 and evidence of pulmonary hypertension (PHT), or be transfusion nai{dotless}̈ve. The median time to thrombosis following splenectomy was 8 years. Patients with an NRBC count ≥ 300 × 106 L-1, a platelet count ≥ 500 × 109 L-1, or who were transfusion naive also had a shorter time to thrombosis following splenectomy. Conclusion: Splenectomized TI patients who will develop TEE may be identified early on by high NRBC and platelet counts, evidence of PHT, and transfusion naivety.

Original languageEnglish
Pages (from-to)2152-2158
Number of pages7
JournalJournal of Thrombosis and Haemostasis
Volume8
Issue number10
DOIs
Publication statusPublished - Oct 2010

Fingerprint

beta-Thalassemia
Splenectomy
Thrombosis
Erythrocyte Count
Platelet Count
Age Groups
Pulmonary Hypertension
Middle East
Thrombophilia
Italy
Registries
Stroke
Demography

Keywords

  • Hypercoagulability
  • Splenectomy
  • Thalassemia intermedia
  • Thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Taher, A. T., Musallam, K. M., Karimi, M., El-Beshlawy, A., Belhoul, K., Daar, S., ... Cappellini, M. D. (2010). Splenectomy and thrombosis: The case of thalassemia intermedia. Journal of Thrombosis and Haemostasis, 8(10), 2152-2158. https://doi.org/10.1111/j.1538-7836.2010.03940.x

Splenectomy and thrombosis : The case of thalassemia intermedia. / Taher, A. T.; Musallam, K. M.; Karimi, M.; El-Beshlawy, A.; Belhoul, K.; Daar, S.; Saned, M.; Cesaretti, C.; Cappellini, M. D.

In: Journal of Thrombosis and Haemostasis, Vol. 8, No. 10, 10.2010, p. 2152-2158.

Research output: Contribution to journalArticle

Taher, AT, Musallam, KM, Karimi, M, El-Beshlawy, A, Belhoul, K, Daar, S, Saned, M, Cesaretti, C & Cappellini, MD 2010, 'Splenectomy and thrombosis: The case of thalassemia intermedia', Journal of Thrombosis and Haemostasis, vol. 8, no. 10, pp. 2152-2158. https://doi.org/10.1111/j.1538-7836.2010.03940.x
Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S et al. Splenectomy and thrombosis: The case of thalassemia intermedia. Journal of Thrombosis and Haemostasis. 2010 Oct;8(10):2152-2158. https://doi.org/10.1111/j.1538-7836.2010.03940.x
Taher, A. T. ; Musallam, K. M. ; Karimi, M. ; El-Beshlawy, A. ; Belhoul, K. ; Daar, S. ; Saned, M. ; Cesaretti, C. ; Cappellini, M. D. / Splenectomy and thrombosis : The case of thalassemia intermedia. In: Journal of Thrombosis and Haemostasis. 2010 ; Vol. 8, No. 10. pp. 2152-2158.
@article{ed4c0a829828420a9291a9beee349cec,
title = "Splenectomy and thrombosis: The case of thalassemia intermedia",
abstract = "Background: Hypercoagulability in splenectomized patients with thalassemia intermedia (TI) has been extensively evaluated. However, clinical and laboratory characteristics of patients who eventually develop overt thromboembolic events (TEE) are poorly studied. Patients/Methods: Three Groups of TI patients (n = 73 each) were retrospectively identified from a registry involving six centers across the Middle East and Italy: Group I, all splenectomized patients with a documented TEE; Group II, age- and sex-matched splenectomized patients without TEE; and Group III, age- and sex-matched nonsplenectomized patients without TEE. Retrieved data included demographics, laboratory parameters, clinical complications, and received treatments that may influence TEE development, and reflected the period prior to TEE occurrence in Group I. Results: The mean age of Group I patients at development of TEE was 33.1 ± 11.7 years, with a male to female ratio of 33:40. TEE were predominantly venous (95{\%}) while four patients (5{\%}) had documented stroke. Among studied parameters, Group I patients weremore likely to have a nucleated red blood cell (NRBC) count ≥ 300 × 106 L-1, a platelet count ≥ 500 × 109 L-1 and evidence of pulmonary hypertension (PHT), or be transfusion nai{dotless}̈ve. The median time to thrombosis following splenectomy was 8 years. Patients with an NRBC count ≥ 300 × 106 L-1, a platelet count ≥ 500 × 109 L-1, or who were transfusion naive also had a shorter time to thrombosis following splenectomy. Conclusion: Splenectomized TI patients who will develop TEE may be identified early on by high NRBC and platelet counts, evidence of PHT, and transfusion naivety.",
keywords = "Hypercoagulability, Splenectomy, Thalassemia intermedia, Thromboembolism",
author = "Taher, {A. T.} and Musallam, {K. M.} and M. Karimi and A. El-Beshlawy and K. Belhoul and S. Daar and M. Saned and C. Cesaretti and Cappellini, {M. D.}",
year = "2010",
month = "10",
doi = "10.1111/j.1538-7836.2010.03940.x",
language = "English",
volume = "8",
pages = "2152--2158",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Splenectomy and thrombosis

T2 - The case of thalassemia intermedia

AU - Taher, A. T.

AU - Musallam, K. M.

AU - Karimi, M.

AU - El-Beshlawy, A.

AU - Belhoul, K.

AU - Daar, S.

AU - Saned, M.

AU - Cesaretti, C.

AU - Cappellini, M. D.

PY - 2010/10

Y1 - 2010/10

N2 - Background: Hypercoagulability in splenectomized patients with thalassemia intermedia (TI) has been extensively evaluated. However, clinical and laboratory characteristics of patients who eventually develop overt thromboembolic events (TEE) are poorly studied. Patients/Methods: Three Groups of TI patients (n = 73 each) were retrospectively identified from a registry involving six centers across the Middle East and Italy: Group I, all splenectomized patients with a documented TEE; Group II, age- and sex-matched splenectomized patients without TEE; and Group III, age- and sex-matched nonsplenectomized patients without TEE. Retrieved data included demographics, laboratory parameters, clinical complications, and received treatments that may influence TEE development, and reflected the period prior to TEE occurrence in Group I. Results: The mean age of Group I patients at development of TEE was 33.1 ± 11.7 years, with a male to female ratio of 33:40. TEE were predominantly venous (95%) while four patients (5%) had documented stroke. Among studied parameters, Group I patients weremore likely to have a nucleated red blood cell (NRBC) count ≥ 300 × 106 L-1, a platelet count ≥ 500 × 109 L-1 and evidence of pulmonary hypertension (PHT), or be transfusion nai{dotless}̈ve. The median time to thrombosis following splenectomy was 8 years. Patients with an NRBC count ≥ 300 × 106 L-1, a platelet count ≥ 500 × 109 L-1, or who were transfusion naive also had a shorter time to thrombosis following splenectomy. Conclusion: Splenectomized TI patients who will develop TEE may be identified early on by high NRBC and platelet counts, evidence of PHT, and transfusion naivety.

AB - Background: Hypercoagulability in splenectomized patients with thalassemia intermedia (TI) has been extensively evaluated. However, clinical and laboratory characteristics of patients who eventually develop overt thromboembolic events (TEE) are poorly studied. Patients/Methods: Three Groups of TI patients (n = 73 each) were retrospectively identified from a registry involving six centers across the Middle East and Italy: Group I, all splenectomized patients with a documented TEE; Group II, age- and sex-matched splenectomized patients without TEE; and Group III, age- and sex-matched nonsplenectomized patients without TEE. Retrieved data included demographics, laboratory parameters, clinical complications, and received treatments that may influence TEE development, and reflected the period prior to TEE occurrence in Group I. Results: The mean age of Group I patients at development of TEE was 33.1 ± 11.7 years, with a male to female ratio of 33:40. TEE were predominantly venous (95%) while four patients (5%) had documented stroke. Among studied parameters, Group I patients weremore likely to have a nucleated red blood cell (NRBC) count ≥ 300 × 106 L-1, a platelet count ≥ 500 × 109 L-1 and evidence of pulmonary hypertension (PHT), or be transfusion nai{dotless}̈ve. The median time to thrombosis following splenectomy was 8 years. Patients with an NRBC count ≥ 300 × 106 L-1, a platelet count ≥ 500 × 109 L-1, or who were transfusion naive also had a shorter time to thrombosis following splenectomy. Conclusion: Splenectomized TI patients who will develop TEE may be identified early on by high NRBC and platelet counts, evidence of PHT, and transfusion naivety.

KW - Hypercoagulability

KW - Splenectomy

KW - Thalassemia intermedia

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=78649339507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649339507&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2010.03940.x

DO - 10.1111/j.1538-7836.2010.03940.x

M3 - Article

VL - 8

SP - 2152

EP - 2158

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 10

ER -